Understanding the mechanism by which IFNa treatment leads to removal of the HCV virus from an infected cell is of interest to Associate Professor Peter White.
Development of Polymer Nanoparticles for Tumor Chemotherapy
One of the most critical problems in cancerous tumour treatment is the lack of selective toxicity against tumour tissues. We aim to develop polymeric nanoparticles as anti-tumour drug delivery systems to eliminate non-selective toxicity of anticancer agents.
This project is a multidisciplinary research collaboration between BABS and CCIA <http://www.ccia.org.au> and includes an honours project for in-vitro evaluation of anticancer drug-loaded nanoparticles using human tumor cell cultures. It makes use of bioconjugation techniques, drug loading and release assays, cell culture, cell toxicity assays, flow cytometry and fluorescent microscopy. This program employs anti-cancer nanomedicines focusing on functional polymeric biomaterials and tumour chemotherapy.
BABS personnel that are responsible for this project